CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale CEO sold 1,000 shares at $16.17 ($16,174)
- 4 Option exercise Director acquired 11,918 shares (option exercise)
- 4 Planned sale Chief Scientific Officer sold 18,980 shares at an average $15.16 ($287,695)
- 4 Planned sale CEO sold 3,000 shares at an average $15.04 ($45,129)
- 4 Open-market buy Director bought 25,000 shares at $14.59 ($364,673)
- 4 Open-market buy Director bought 4,476 shares at an average $14.14 ($63,306)
- 4 Open-market buy Director bought 2,600 shares at $13.57 ($35,290)
- 4 Open-market buy Director bought 1,512 shares at $13.75 ($20,794)
- 4 Open-market buy Director bought 9,048 shares at an average $13.58 ($122,882)
- 4 Open-market buy Director bought 2,732 shares at an average $12.81 ($34,996)
- 4 Option exercise Chief Financial Officer acquired 9,000 shares (option exercise)
- 4 Planned sale Chief Financial Officer sold 4,086 shares at $12.31 ($50,285)
- 4 Planned sale President & COO sold 1,826 shares at $12.32 ($22,499)
- 4 Shares withheld for taxes CEO gave up 7,604 shares (to pay taxes)
Page 5 of 13 · 242 filings